<div id="readability-page-1">Stock under pressure: Pfizer shares are down over 50% from 2021 highs, weighed by patent risks and COVID product declines. Investor sentiment split: Most analysts rate the stock cautiously, but some see the sell-off as a contrarian buying opportunity. Pipeline in focus: Pfizer is advancing vaccines, oncology, and migraine drugs, and acquired a GLP-1 candidate after ending its own program.</div>

<p>Pfizer's stock has dropped over 50% from its 2021 peak due to patent expirations and declining COVID product sales. Analyst sentiment is divided, with most exercising caution while some view the decline as a contrarian buying opportunity. The company continues to advance its pipeline in vaccines, oncology, and migraine treatments, having acquired a GLP-1 candidate after terminating its internal program.</p>

- Pfizer shares have fallen over 50% since 2021 due to patent risks and declines in COVID product sales.  
- Investor sentiment is divided, with most analysts maintaining a cautious outlook while some view the current sell-off as a chance to buy.  
- The company is focusing on advancing its vaccine programs, oncology, and migraine treatments, and has acquired a GLP-1 candidate after discontinuing its own program.

Pfizer

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VG Health

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bear 3X

ALPS Medical Breakthrough

iShares Global Healthcare

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Pfizer’s deep stock slump sparks debate over long-term value